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Does Pregnancy Influence the
bstitutes?To the Editor: There is insufficient published evidence about the
potential degenerative effects of pregnancy on the homograft and
pulmonary autograft in the aortic position. To assess the associa-
tion between pregnancy and accelerated degeneration of human
aortic valve substitutes, we conducted a retrospective analysis of a
prospective cohort study of female patients who received a human
tissue valve in the aortic position at our institution.
All patients who have received a homograft or autograft in the
aortic position in our center since 1987 are enrolled in an ongoing
prospective follow-up study (1). Patients undergo annual clinical
follow-up and biennial standardized serial echocardiography
(aortic gradient [Vmax]), aortic regurgitation (AoI), and annular
and sinotubular junction diameter (AD and STJ). We identified
108 female patients who underwent 59 homograft and 49 autograft
procedures, and who were50 years old at the time of surgery and
t least 16 years old at the time of study (age 29  13 years).
Informed consent was obtained from the patients to interview
them (December 2010) for additional information on pregnancy
and cardiac status (institutional review board number 2010–272).
Figure 1 Vmax, STJ Diameter, AD, and AoI Marginal Probability
(Top row) Homograft models. (Bottom row) Autograft models. (Shaded grey areaFreestanding root replacement with reimplantation of the coronary
arteries was performed in most patients. Fifteen homograft patients
underwent a subcoronary homograft implantation, and 2 autograft
patients had an inclusion cylinder aortic root replacement.
Outcome was reported according to the 2008 American Asso-
ciation of Thoracic Surgery/European Association of Cardio-
Thoracic Surgery/Society of Thoracic Surgeons guidelines for
reporting mortality and morbidity after cardiac valve interventions.
Mixed-effects models were used to assess changes in echocardio-
graphic measurements over time while accounting for within-
patient correlation between repeated follow-up measurements (2).
Total follow-up was 1,448 patient years and 99% complete.
Ninety-nine patients had 1 echocardiographic examinations
(median 6; range 1 to 11).
Thirty-one patients (13 homografts and 18 autografts) experi-
enced 55 pregnancies, including 48 completed pregnancies, 4
elective abortions for noncardiac reasons, and 3 miscarriages.
Homograft recipients without pregnancies were older than
homograft recipients who became pregnant (35 vs. 28 years;
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November 6, 2012:1989–92p  0.02). There were no other differences in patient character-
istics between homograft and autograft patients without pregnan-
cies and those who became pregnant.
During follow-up, 9 homograft patients and 4 autograft patients
died. Fifteen-year survival in homograft patients was 80.0  7.3%
for patients without pregnancies and 100% for patients with
pregnancies; in autograft patients, this was 94.1  4.0% for
atients without pregnancies and 94.4  5.4% for patients with
regnancies (p  NS).
Fifteen homograft patients required reoperation for a calcified
nd degenerated homograft; 2 additional homograft patients were
eoperated for paravalvular leak. Twelve autograft patients were
eoperated for neoaortic regurgitation and dilation of the neoaortic
oot, including 11 autograft replacements and 1 valve-sparing
ortic root replacement (Yacoub procedure). Freedom from aortic
alve reoperation at 15 years was 63% (95% confidence interval
CI]: 57% to 69%) in homograft patients; in autograft patients,
his was 75% (95% CI: 63% to 87%). Freedom from reoperation
as comparable between patients who experienced pregnancy and
hose who did not, in both homograft and autograft recipients
p  NS).
Figure 1 shows progression of Vmax, STJ diameter, AD, and
oI over time. Pregnancy was not associated with changes in Vmax
over time, STJ diameter over time, AD over time, or AoI grade
over time for either valve type.
Pregnancy is known to produce significant hemodynamic changes,
with an increase in heart rate, plasma volume, and cardiac output (3).
This may impose a burden on biological valve substitutes, accelerating
degeneration. However, we found that pregnancy was not associated
with either homograft or pulmonary autograft valve reoperation and
echocardiographic valve function over time. This is in concordance
with previous, but very limited, evidence (4,5).
The question remains as to what the best valve substitute choice
is for young female patients who require aortic valve replacement,
and who may contemplate pregnancy. Bioprosthetic valves are an
option, but valvular deterioration seems to accelerate during
pregnancy (6). Mechanical prostheses are far from ideal during
pregnancy because of anticoagulation therapy-related complica-
tions, although in some patients mechanical valves are the only
option. Human tissue valves do not require anticoagulation ther-
apy and have good hemodynamic performance, but ho-
mografts—in contrast to autografts—do not increase in size with
the growing child. In addition, autografts have a superior hemo-
dynamic profile (7), which particularly during pregnancy haspotential beneficial effects on cardiac function. In contrast, neo-
aortic root dilation and neoaortic regurgitation cause an increased
need for reoperation (8).
Because human tissue valve durability is not influenced by
pregnancy, it offers an attractive biological option for aortic valve
replacement in young female patients. Young female patients who
(may) contemplate pregnancy should consider human tissue valves
as a suitable aortic valve substitute.
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